Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.56 |
| ▸ | PPARA | Q07869 | 16/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7965896 | 0.92 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL7963791 | 0.91 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL7965982 | 0.90 | PPARA (0.57) | PPARGPPARAPPARD | |
| SCHEMBL6735926 | 0.83 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL7954590 | 0.82 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL7968057 | 0.82 | PPARA (0.49) | PPARGPPARAPPARD | |
| SCHEMBL6741132 | 0.81 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL7965707 | 0.81 | PPARA (0.70) | PPARGPPARAPPARD | |
| SCHEMBL7968986 | 0.80 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL6737545 | 0.79 | PPARG (0.65) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6300339-B1 | USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE | NOVO NORDISK A/S (DK) | 2001-10-09 | — | — | US | claimed |
| US-6300339-B1 | USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE | NOVO NORDISK A/S (DK) | 2001-10-09 | — | — | US | disclosed |